Sanofi: Sarclisa Combination Provides Unprecedented Median P

PARIS (dpa-AFX) - French drug major Sanofi (SNYNF, SNY) said that Sarclisa (isatuximab) combination provided unprecedented median progression free survival in patients with relapsed multiple myeloma

Related Keywords

France , Paris , France General , French , , Drug Administration , Sanofi , Sarclisa , Combination , Rovides , Unprecedented , Comedian , Relapsed , Multiple , Myeloma ,